SK279262B6 - Protivírusová zmes, farmaceutický prostriedok s je - Google Patents

Protivírusová zmes, farmaceutický prostriedok s je Download PDF

Info

Publication number: SK279262B6
Authority: SK; Slovakia
Prior art keywords: azt; pharmaceutically acceptable; combination; antiviral; compound
Prior art date: 1991-05-16

Application number

SK1199-93A

Other languages

English (en)

Slovak (sk)

Other versions

SK119993A3 (en

Inventor

Janet M. Cameron

Nicholas Cammack

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-16

Filing date

1992-05-11

Publication date

1998-08-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK279262(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-05-16 Priority claimed from GB919110624A external-priority patent/GB9110624D0/en

1991-10-08 Priority claimed from GB919121381A external-priority patent/GB9121381D0/en

1991-11-06 Priority claimed from GB919123581A external-priority patent/GB9123581D0/en

1992-05-11 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

1994-04-06 Publication of SK119993A3 publication Critical patent/SK119993A3/sk

1998-08-05 Publication of SK279262B6 publication Critical patent/SK279262B6/sk

Links

230000000840 anti-viral effect Effects 0.000 title claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 30
239000000203 mixture Substances 0.000 claims description 32
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 11
-1 2-hydroxymethyl-1,3-oxathiolan-5-yl Chemical group 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000003814 drug Substances 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 8
230000002265 prevention Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 41
239000000243 solution Substances 0.000 description 32
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
239000004480 active ingredient Substances 0.000 description 20
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
229960002555 zidovudine Drugs 0.000 description 18
241000725303 Human immunodeficiency virus Species 0.000 description 14
239000000047 product Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
210000004027 cell Anatomy 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000007787 solid Substances 0.000 description 11
239000003112 inhibitor Substances 0.000 description 10
238000000034 method Methods 0.000 description 10
230000010076 replication Effects 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000000543 intermediate Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000126 substance Substances 0.000 description 8
150000002148 esters Chemical class 0.000 description 7
230000014759 maintenance of location Effects 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000002195 synergetic effect Effects 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 6
239000000758 substrate Substances 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
231100000135 cytotoxicity Toxicity 0.000 description 5
230000003013 cytotoxicity Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
239000002585 base Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000004296 chiral HPLC Methods 0.000 description 4
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000001802 infusion Methods 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
239000000463 material Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 3
239000007921 spray Substances 0.000 description 3
SMKDHPIQHWRJFP-UHFFFAOYSA-N (5-methoxy-1,3-oxathiolan-2-yl)methyl benzoate Chemical compound O1C(OC)CSC1COC(=O)C1=CC=CC=C1 SMKDHPIQHWRJFP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
SWOOIHFMFZUHOC-QWHCGFSZSA-N [(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COC(=O)C=2C=CC=CC=2)SC1 SWOOIHFMFZUHOC-QWHCGFSZSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical group C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
NHSVBZUCAFSNBR-UHFFFAOYSA-N 2,2-dimethoxyethanethiol Chemical compound COC(CS)OC NHSVBZUCAFSNBR-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
OQEDEGGYERFFGP-UHFFFAOYSA-N 2-oxoethyl benzoate Chemical compound O=CCOC(=O)C1=CC=CC=C1 OQEDEGGYERFFGP-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 description 1
101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010051779 Bone marrow toxicity Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
101710175714 Tyrosine aminotransferase Proteins 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
QYKULYCDZYBCJJ-QWHCGFSZSA-N [(2r,5s)-5-(2,4-dioxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound N1([C@H]2O[C@H](SC2)COC(=O)C=2C=CC=CC=2)C=CC(=O)NC1=O QYKULYCDZYBCJJ-QWHCGFSZSA-N 0.000 description 1
QYKULYCDZYBCJJ-UHFFFAOYSA-N [5-(2,4-dioxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(SC1)OC1N1C=CC(=O)NC1=O QYKULYCDZYBCJJ-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
231100000366 bone marrow toxicity Toxicity 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000037384 skin absorption Effects 0.000 description 1
231100000274 skin absorption Toxicity 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1199-93A 1991-05-16 1992-05-11 Protivírusová zmes, farmaceutický prostriedok s je SK279262B6 (sk)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB919110624A GB9110624D0 (en)	1991-05-16	1991-05-16	Combinations
GB919121381A GB9121381D0 (en)	1991-10-08	1991-10-08	Combinations
GB919123581A GB9123581D0 (en)	1991-11-06	1991-11-06	Combinations
PCT/EP1992/001106 WO1992020344A1 (en)	1991-05-16	1992-05-11	Antiviral combinations containing nucleoside analogs

Publications (2)

Publication Number	Publication Date
SK119993A3 SK119993A3 (en)	1994-04-06
SK279262B6 true SK279262B6 (sk)	1998-08-05

Family

ID=27265656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1199-93A SK279262B6 (sk)	1991-05-16	1992-05-11	Protivírusová zmes, farmaceutický prostriedok s je

Country Status (25)

Country	Link
US (2)	US5627186A (no)
EP (1)	EP0513917B2 (no)
JP (1)	JP2868671B2 (no)
KR (1)	KR100246687B1 (no)
CN (1)	CN1045961C (no)
AT (1)	ATE131730T1 (no)
AU (2)	AU1787492A (no)
CA (1)	CA2068790C (no)
CZ (1)	CZ285232B6 (no)
DE (2)	DE69206876T3 (no)
DK (1)	DK0513917T4 (no)
ES (1)	ES2083668T5 (no)
GR (1)	GR3018915T3 (no)
HK (1)	HK78897A (no)
IE (1)	IE73261B1 (no)
IL (1)	IL101883A (no)
LU (1)	LU90234I2 (no)
MX (1)	MX9202279A (no)
NL (1)	NL980018I2 (no)
NO (2)	NO301690B1 (no)
NZ (2)	NZ299240A (no)
OA (1)	OA10058A (no)
SK (1)	SK279262B6 (no)
TW (1)	TW273550B (no)
WO (1)	WO1992020344A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9009861D0 (en) *	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US6812233B1 (en)	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
ATE184787T1 (de) *	1992-05-13	1999-10-15	Wellcome Found	Therapeutische kombinationen
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
GB9215178D0 (en) *	1992-07-16	1992-08-26	Glaxo Group Ltd	Antiviral combinations
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) *	1994-05-24	1996-08-23	Laphal Laboratoires Sa	Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
GB9503850D0 (en) *	1995-02-25	1995-04-19	Glaxo Group Ltd	Medicaments
MY115461A (en) *	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
AP9801419A0 (en)	1996-06-25	1998-12-31	Glaxo Group Ltd	Combination comprising VX478, zidovudine, FTC and or 3
US6113920A (en) *	1996-10-31	2000-09-05	Glaxo Wellcome Inc.	Pharmaceutical compositions
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions
TW536403B (en) *	1997-03-24	2003-06-11	Glaxo Group Ltd	An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6495553B1 (en)	1997-08-08	2002-12-17	Newbiotics, Inc.	Methods and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
JP2002500880A (ja)	1998-01-23	2002-01-15	ニューバイオティックスインコーポレイテッド	酵素に触媒される治療剤
EP1089741A1 (en) *	1998-06-24	2001-04-11	Emory University	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
AU774492B2 (en)	1999-07-22	2004-07-01	Celmed Oncology (Usa) Inc.	Methods for treating therapy-resistant tumors
US6432966B2 (en)	1999-10-29	2002-08-13	Smithkline Beecham Corporation	Antiviral combinations
AP2220A (en) *	2001-05-11	2011-03-24	Cipla Medpro Pty Ltd	Pharmaceutical composition.
JP2006508134A (ja) *	2002-11-08	2006-03-09	グラクソ　グループ　リミテッド	医薬組成物
US20060246130A1 (en)	2003-01-14	2006-11-02	Dahl Terrence C	Compositions and methods for combination antiviral therapy
WO2004103360A1 (ja)	2003-05-22	2004-12-02	Lead Chemical Co.,Ltd.	抗ウイルス作用を有する化合物および配合剤
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
EP1975923B1 (en) *	2007-03-28	2016-04-27	Nuance Communications, Inc.	Multilingual non-native speech recognition
WO2010137027A1 (en)	2009-05-27	2010-12-02	Hetero Research Foundation	Solid oral dosage forms of lamivudine
CN104203275A (zh)	2010-06-09	2014-12-10	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
AU2013229274A1 (en)	2012-03-05	2014-09-04	Cipla Limited	Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1214611B (it) *	1985-05-22	1990-01-18	Schiena Ricerche	Composti per uso cosmetico dermatologico e relative composizioni.
GB8717955D0 (en) *	1987-07-29	1987-09-03	Fujisawa Pharmaceutical Co	Prevention & treatment of aids
US5270464A (en) *	1989-03-14	1993-12-14	Janssen Pharmaceutica N.V.	Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
JPH02504283A (ja) *	1988-03-23	1990-12-06	ニューヨーク　ユニバーシィティ	芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
EP0362359A4 (en) *	1988-03-23	1991-11-21	New York University	Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
ES2038847T3 (es) *	1988-09-28	1993-08-01	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
DE58902899D1 (de) *	1988-12-14	1993-01-14	Ciba Geigy Ag	2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
US5132291A (en) *	1989-01-24	1992-07-21	Gensia Pharmaceuticals, Inc.	Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) *	1989-02-23	1995-01-24	Janssen Pharmaceutica Nv	History of tetrahydroimidazo [1,4] benzodiazepine-2-thione, their preparation and pharmaceutical preparations containing them
NZ232912A (en) *	1989-03-17	1992-06-25	Oncogen Ltd Lp	Synergistic composition of nucleoside derivatives for inhibiting hiv
US5011829A (en) *	1989-06-02	1991-04-30	G. D. Searle & Co.	Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) †	1989-07-19	1991-03-18	Bo Fredrik Oeberg	Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5116823A (en) *	1990-02-27	1992-05-26	Roger Williams General Hospital	Drug combinations containing AZT
GB9009861D0 (en) *	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination

1992
- 1992-05-11 ES ES92201328T patent/ES2083668T5/es not_active Expired - Lifetime
- 1992-05-11 AU AU17874/92A patent/AU1787492A/en not_active Abandoned
- 1992-05-11 DE DE69206876T patent/DE69206876T3/de not_active Expired - Lifetime
- 1992-05-11 CZ CZ932428A patent/CZ285232B6/cs not_active IP Right Cessation
- 1992-05-11 SK SK1199-93A patent/SK279262B6/sk not_active IP Right Cessation
- 1992-05-11 DK DK92201328T patent/DK0513917T4/da active
- 1992-05-11 EP EP92201328A patent/EP0513917B2/en not_active Expired - Lifetime
- 1992-05-11 DE DE1998175016 patent/DE19875016I2/de active Active
- 1992-05-11 AT AT92201328T patent/ATE131730T1/de active
- 1992-05-11 WO PCT/EP1992/001106 patent/WO1992020344A1/en active IP Right Grant
- 1992-05-15 NZ NZ299240A patent/NZ299240A/en not_active IP Right Cessation
- 1992-05-15 KR KR1019920008239A patent/KR100246687B1/ko not_active IP Right Cessation
- 1992-05-15 JP JP4148384A patent/JP2868671B2/ja not_active Expired - Lifetime
- 1992-05-15 MX MX9202279A patent/MX9202279A/es not_active IP Right Cessation
- 1992-05-15 NZ NZ242754A patent/NZ242754A/en not_active IP Right Cessation
- 1992-05-15 AU AU16279/92A patent/AU661307B2/en not_active Expired
- 1992-05-15 NO NO921947A patent/NO301690B1/no not_active IP Right Cessation
- 1992-05-15 IL IL10188392A patent/IL101883A/en not_active IP Right Cessation
- 1992-05-15 TW TW081103780A patent/TW273550B/zh not_active IP Right Cessation
- 1992-05-15 CA CA002068790A patent/CA2068790C/en not_active Expired - Lifetime
- 1992-05-15 CN CN92104553A patent/CN1045961C/zh not_active Expired - Lifetime
- 1992-07-01 IE IE921566A patent/IE73261B1/en not_active IP Right Cessation
1993
- 1993-10-22 OA OA60427A patent/OA10058A/en unknown
1994
- 1994-03-28 US US08/219,176 patent/US5627186A/en not_active Expired - Lifetime
1996
- 1996-02-07 GR GR960400321T patent/GR3018915T3/el unknown
- 1996-02-22 US US08/605,610 patent/US5859021A/en not_active Expired - Lifetime
1997
- 1997-06-12 HK HK78897A patent/HK78897A/xx not_active IP Right Cessation
1998
- 1998-04-24 LU LU90234C patent/LU90234I2/fr unknown
- 1998-04-28 NL NL980018C patent/NL980018I2/nl unknown
1999
- 1999-07-22 NO NO1999018C patent/NO1999018I1/no unknown

Also Published As

Publication number	Publication date
CA2068790A1 (en)	1992-11-17
IL101883A (en)	1998-10-30
AU1787492A (en)	1992-12-30
MX9202279A (es)	1992-11-01
NO921947L (no)	1992-11-17
JPH06234641A (ja)	1994-08-23
LU90234I2 (fr)	1998-06-24
EP0513917A1 (en)	1992-11-19
NZ242754A (en)	1996-11-26
KR920021148A (ko)	1992-12-18
US5627186A (en)	1997-05-06
CZ242893A3 (en)	1994-07-13
TW273550B (no)	1996-04-01
SK119993A3 (en)	1994-04-06
IE73261B1 (en)	1997-05-21
DK0513917T3 (da)	1996-02-05
IE921566A1 (en)	1992-11-18
NO301690B1 (no)	1997-12-01
KR100246687B1 (ko)	2000-04-01
OA10058A (en)	1996-10-14
ATE131730T1 (de)	1996-01-15
CZ285232B6 (cs)	1999-06-16
NL980018I2 (nl)	1998-11-02
DE69206876D1 (de)	1996-02-01
ES2083668T3 (es)	1996-04-16
AU1627992A (en)	1992-11-19
DK0513917T4 (da)	2001-06-25
DE69206876T3 (de)	2004-08-12
CN1068570A (zh)	1993-02-03
CN1045961C (zh)	1999-10-27
JP2868671B2 (ja)	1999-03-10
WO1992020344A1 (en)	1992-11-26
AU661307B2 (en)	1995-07-20
DE19875016I2 (de)	2004-07-01
HK78897A (en)	1997-06-20
NL980018I1 (nl)	1998-07-01
EP0513917B1 (en)	1995-12-20
ES2083668T5 (es)	2001-06-16
CA2068790C (en)	2005-06-07
GR3018915T3 (en)	1996-05-31
NO921947D0 (no)	1992-05-15
EP0513917B2 (en)	2001-03-07
IL101883A0 (en)	1992-12-30
NZ299240A (en)	2004-11-26
DE69206876T2 (de)	1996-05-23
US5859021A (en)	1999-01-12
NO1999018I1 (no)	1999-07-22

Publication	Publication Date	Title
SK279262B6 (sk)	1998-08-05	Protivírusová zmes, farmaceutický prostriedok s je
KR960007532B1 (ko)	1996-06-05	1,3-옥사티오란 뉴클레오시드 동족체
WO2003053989A1 (en)	2003-07-03	Masked phosphate containing nucleoside derivatives and their use as antivirals
US20060217345A1 (en)	2006-09-28	Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases
US11618765B2 (en)	2023-04-04	Broad-spectrum antiviral nucleoside derivatives
AU775355B2 (en)	2004-07-29	Pyrazolidinol compounds
RU2139059C1 (ru)	1999-10-10	Противовирусная комбинация, содержащая нуклеозидный аналог, фармацевтическая композиция, способ лечения
AP90A (en)	1990-07-14	Therapeutic nucleosides.
FI111723B (fi)	2003-09-15	Menetelmä valmistaa cis-4-amino-1-(2-hydroksimetyyli-1,3-oksatiolan-5- yyli)-(1H)-pyrimidin-2-onin (-)enantiomeeriä käytettäväksi virustenvastaisena aineena
US20100144664A1 (en)	2010-06-10	Carbocyclic compounds and methods for treating emerging disease, including influenza and venezuela equine encephalitis virus
SI9110782A (sl)	1997-02-28	1,3-oksatiolanski nukleozidni analogi

Legal Events

Date	Code	Title	Description
2012-07-03	MK4A	Patent expired	Expiry date: 20120511